Injunction halts change to long-standing safety-net drug-pricing program

Under HHS’s rebate model program, safety-net providers would have to pay millions upfront for drugs that would otherwise be spent on low-income patients.

Hospital groups have blocked a contentious new drug-funding model they claimed would cost millions of dollars in lost discounts and have a detrimental effect on care for low-income and rural patients.

On December 29, 2025, the US District Court for the District of Maine issued a preliminary injunction blocking the US Department

Register for free to keep reading

To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.

  • Unlimited access to industry insights
  • Stay on top of key rules and regulatory changes with our Rules Navigator
  • Ad-free experience with no distractions
  • Regular podcasts from trusted external experts
  • Fresh compliance and regulatory content every day